By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Novo Nordisk's stock dropped by more than 4% following disappointing results from a Phase 2a trial of its obesity pill, Monlunabant. The experimental drug, acquired through Inversago Pharmaceuticals, ...

The company said at its capital markets day in March that it expected that weight loss could reach 15%, on par with its ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

It’s a question that some users of semaglutide and tirzepatide injections, sold as Wegovy and Zepbound for weight loss, have ...

Whether positive or negative, your mood may feel different on GLP-1 medications. Researchers share why that might be and how ...

Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military ...

The device is a variant of Neuralink's brain implant technology, in this case designed to "enable even those who have lost both eyes" to see, according to owner Elon Musk. Separately, progress is ...

For patients on a 12-month plan, Hims offers a semaglutide injection for $199 a month. Ozempic and Wegovy carry high list prices of $935.77 and $1,349.02, respectively, for a month’s supply, according ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

Ozempic is not approved for use in weight loss, however, many people have been taking the drug for this purpose. Semaglutide was approved for weight loss purposes under another name—Wegovy—which has a ...